Active substance
Nifurtimox
- US FDA 1
- WHO EML 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LAMPIT | 30MG; 120MG | tablet · oral | BAYER HEALTHCARE | Prescription | 6 Aug 2020 |
WHO WHO Model List of Essential Medicines (2025)
- 6.5.5.2. American trypanosomiasis · core
Chagas disease
Oral > Solid > tablet: 30 mg (scored); 120 mg (scored) - 6.5.5.1.2. Medicines for the treatment of 2nd stage African trypanosomiasis · core
Gambiense trypanosomiasis
Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
Safety signals and safety-related labeling changes
- US FDA 2 Jun 2023 LAMPIT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.